We welcome initiatives that aim to harmonise rules, but notes these often raise the overall cost and impact by harmonising to the highest common denominator. The key points we would like to emphasise in this consultation are: 1. The need to support investment in R&D and innovation in the EU, to avoid disincentives to investment through by allowing lower market entry costs to commercial competitors free-riders.
HUV
Huvepharma
Company · Belgium · EU Transparency Register 375683914911-93
1
position filed
in the 639 files tracked
1
legislative file
of 639 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 639 consultation files tracked so far (53,766 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1161 companies & groups on this site, they rank #951 by legislative files engaged — a count of participation, not a measure of influence.
0.3
declared lobbying FTE
self-declared
€25K+
declared costs / yr (floor)
1
EP accreditations
as declared to the register
2014
in the register since
Declares membership of
- Huvepharma is a member of AnimalHealthEurope and FEFANA at EU level, together with several national federations
Self-declared to the EU Transparency Register (snapshot 14 Sept 2026).
- Register category
- Companies & groups
- Head office
- Antwerpen, Belgium
Self-declared to the EU Transparency Register (snapshot 14 Sept 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Huvepharma in PolicySpeak: request access →
Work at Huvepharma? so we know who speaks for it.
Their record over time
Huvepharma filed 1 position on 16 Aug 2022, across 1 of the 639 legislative files tracked here.
What they argued
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Huvepharma next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from Huvepharma’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.